Home > Insider Trading > Filing (0001209191-17-060103)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479290	Revance Therapeutics Inc.	RVNC	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1225755	P Lauren Silvernail	C/O Revance Therapeutics, Inc. 7555 Gateway Boulevard Newark CA 94560	Cfo, Cbo & Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-07	10,000	$8.70	59,006	No	4	M	Direct
Common Stock	Disposition	2017-11-07	10,000	$26.83	49,006	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2017-11-07	10,000	$0.00	10,000	$8.70

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
63,373		2023-05-23	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail.
The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.40 to $27.25. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The Option became fully vested as of March 18, 2017.